"What" Series

What is Clinical Benefit Rate (CBR) in Clinical Trials?

16 October 2023
2 min read

Clinical Benefit Rate (CBR) is defined as the percentage of advanced cancer patients who achieve complete remission, partial remission, or at least six months of stable disease after treatment. Some argue that CBR should not be used at all, because it does not measure clinical benefit. However, its use is also supported as, like DCR, CBR can be used to quickly assess the anti-cancer activity and can further capture the stability of the disease.

Keep Reading
Back to all blogs →
BridgeBio and Resilience declares a collaboration aiming to progress BBP-631, BBP-812
Latest Hotspot
3 min read
BridgeBio and Resilience declares a collaboration aiming to progress BBP-631, BBP-812
16 October 2023
BridgeBio Pharma and National Resilience Inc., which focus on genetic diseases, cancer pharmaceuticals, and tech-driven biomanufacturing respectively, announced a partnership to develop and produce BBP-812 and BBP-631, gene therapies for Canavan disease and congenital adrenal hyperplasia.
Read →
A new approach to the development of targeted drugs: PROTACs
Advanced Tech.
7 min read
A new approach to the development of targeted drugs: PROTACs
16 October 2023
Proteolysis Targeting Chimeras (PROTACs) technology is a new protein degradation strategy that has emerged in recent years.
Read →
What is Pathological Complete Response (pCR) in Clinical Trials?
"What" Series
2 min read
What is Pathological Complete Response (pCR) in Clinical Trials?
16 October 2023
Pathological Complete Response (pCR) is commonly used as a surrogate marker for breast cancer and is defined as the absence of residual invasive cancer in the resected breast tissue and evaluated regional lymph node.
Read →
Disc Medicine Launches Phase 1 Trial of DISC-3405 with Healthy Participants
Latest Hotspot
3 min read
Disc Medicine Launches Phase 1 Trial of DISC-3405 with Healthy Participants
16 October 2023
Disc Medicine has revealed the start of a Phase 1 trial for DISC-3405 (formerly MWTX-003) with healthy participants.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.